Compliance & Communications
Public filings and regulatory disclosures.
FDA inspection reports, court filings, and state sterile-compounding inspection documents. Available for procurement, audit, and legal review.

FDA
FDA inspection filings.
FDA inspection reports (Form 483 and Establishment Inspection Reports), our formal responses, and litigation documents tied to FDA inspectional activity.

State
State sterile compounding inspection.
The most recent state sterile-compounding inspection acceptance letter for Hybrid Pharma's Deerfield Beach facility, confirming the Corrective Action Plan submitted in response to the February 2026 inspection.

DEA
DEA-registered research.
Analytical work performed under DEA registration. Click any poster to open the full image in a new tab.

Full ISRP 2026 poster
Development and Validation of Lyophilized Psilocybin for IV Administration

HPLC stability in syringe
In-Use Testing of Reconstituted Psilocybin in Syringe

Related-substance characterization
Impurity at RRT 1.9

HPLC peak analysis at 5 / 25 / 40 °C
Extended Stability Testing of Lyophilized Product
News & updates
Latest from compliance.
Recent inspection outcomes, license renewals, and audit-pack updates.
News feed coming soon. Pull entries from the legacy site's/news/archive and they'll appear here.
Need documentation that isn't listed?
Procurement, audit, and legal review teams can request the full audit pack — cGMP procedures, environmental monitoring records, batch records, USP <797> certification, and sterility validation.